HRAS and neoplasm: In support to this concept, recent studies on matched primary tumours and biopsies at relapse clarified that genetic alteration in CHD5, DOCK8, PTPN14, HRAS and KRAS genes and losses on chromosome 9p acquired during tumour progression suggesting a likely tailored therapy against these genetic alterations in patients at the disease recurrence [126].